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Abstract: Self renewal, extensive proliferation and multilineage differentiation ability in vitro and in vivo make mesen-
chymal stem cells (MSCs) powerful tools for tissue engineering. Beyond their potential uses in regenerative medicine, an 
emerging field of research aims to utilize MSCs for anti-cancer treatment. These strategies are based on the remarkable 
ability of MSCs to localize and integrate into tumor stroma and deliver anti-cancer agents (US20100055167, 
US20120207725, US20120010499). Genetically engineered MSCs can specifically target different tumor types and 
locally secrete therapeutic proteins such as interferons  and , interleukins 2 and 12 or chemokine CX3CL1 
(US20110027239, US20120087901, WO2012071527). In addition, MSCs have also been engineered to deliver oncolytic 
viruses, for targeted chemotherapy using enzyme prodrug conversion or for inducing tumor cell apoptosis by delivering 
tumor necrosis factor-related apoptosis inducing ligand (TRAIL) (WO2012106281). The patent databases FPO and 
Delphion were used to locate patents that were published between 2005 and 2013. Here, we present the current progress 
and the most recent patents on MSC anti-cancer drug delivery systems and discuss future directions in the field. 
Keywords: Cancer therapy, drug delivery, mesenchymal stem cells.  
INTRODUCTION 
 One of the many challenges of cancer treatment concerns 
the delivery of anticancer drugs to the site of the tumor. 
Bone marrow-derived stem cells (BMSCs) have the ability to 
migrate specifically to, and incorporate within tumors, which 
makes them a potentially exciting drug delivery tool [1].  
 The BMSCs include two groups of cells: haematopoietic 
progenitor stem cells (HSCs) and mesenchymal stem cells 
(MSCs) [2]. The International Society for Cellular Therapy 
has recommended minimum criteria based on cell adherent 
properties, surface markers and differentiation potential for 
defining multi-potent human MSCs (Table 1) [3, 4].  
 The MSC characteristics of extensive proliferation, self-
renewal and multilineage differentiation make them a prom-
ising tool for tissue engineering and regenerative medicine 
[5-9]. During both proliferation and differentiation, MSCs 
interact with other cells through both cell-cell interactions 
and paracrine signaling, involving the secretion of growth 
factors, cytokines, antifibrotic or angiogenic mediators [10, 
11]. 
 Primary MSC targets are regions of new stroma for-
mation including sites of hematopoiesis, inflammation, and 
injury. Interestingly, MSC localization and persistence in 
solid tumor stromal tissue have also been reported [12-16]. 
Furthermore, exogenously delivered MSCs’ are also  
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preferentially locallized to tumors. These tumor tropism 
abilities make MSCs a suitable tool for tumor therapy as 
delivery vehicles for various biological agents [17, 18]. Nu-
merous in vivo studies using animal tumor models have 
shown that these cells preferentially migrate to tumors. Re-
gardless of delivery methods (intravenously [19-24], intrape-
ritoneal [25] or intracerebral [20]) MSCs predictably mi-
grate, incorporate, and survive in cancer tissue. One explana-
tion is that MSCs have a variety of surface chemokine and 
cytokine receptors that respond functionally to a large array 
of molecules that are secreted by tumors [16, 26, 27]. 
 In several studies, immunoregulatory and proliferative 
effects of MSCs on tumor growth were investigated leading 
to two main mechanisms that are likely involved in the en-
hancement of tumor growth by MSCs. First, cell-to-cell 
cross talk between MSCs and tumor cells contribute to tumor 
progression [28, 29], and second, the suppressive effects of 
MSCs on the immune system facilitate tumor genesis, as 
shown for the inhibition of melanoma rejection, possibly 
mediated by regulatory CD8
+
 T cells [15, 30]. 
 The ability of MSCs to migrate specifically to tumors has 
led several groups to engage them for delivering anticancer 
agents (Table 2). There are numerous studies reporting engi-
neered MSCs specifically targeting different tumor types 
followed by local secretion of therapeutic proteins, such as 
interferon  (IFN) [31, 32] and  (IFN) [17, 20, 23, 31, 
32], immunostimulatory interleukin (IL)12 [33], immuno-
modulatory cytokine IL2 [34] or chemokine CX3CL1 (frac-
talkine) [22]. MSCs have also been engineered to deliver 
conditional replicative oncolytic viruses to reduce tumor 
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growth and metastasis in vivo [25, 35-37]. Furthermore, 
MSCs serve as therapeutic cytoreagents for gene therapy as 
well as vehicles for targeted chemotherapy with an enzyme 
prodrug conversion [38-43]. Strong antitumor effects have 
been reported following administration of gene modified 
MSCs expressing tumor necrosis factor-related apoptosis 
inducing ligand (TRAIL) [19, 44-47]. In experimental cancer 
models, TRAIL was found to cause apoptosis selectively in 
glioma and lung cancer, while sparing non-cancer cells. 
Also, MSCs secreting IL-12 [33, 48, 49] or IL-2 [34, 50] 
were shown to initiate an immunoreaction and stimulate in-
flammatory cell infiltration in the tumor tissue but did not 
cause systemic toxicity [49].  
 MSCs can be isolated from adult tissues, including bone, 
fat, skeletal muscle, synovium, dental pulp, and fetal tissues, 
including umbilical cord blood, placenta, amniotic mem-
branes and fluid, and Wharton’s jelly [8, 29]. Although, 
MSCs derived from different sources share many traits, they 
differ in several aspects of gene expression and physiology 
[29], leading some to view the proposed use of MSCs in 
cancer therapies as dangerous. New facts about MSC promo-
tion of tumor vascularization and growth have been reported 
and are discussed later in this text.  
RECENT PATENTS RELATING TO MSCs AND 
THEIR USE AS ANTICANCER DRUG DELIVERY 
SYSTEMS 
 It is especially important to consider the role of MSCs in 
the context of their immunosuppressive, reparative and angi-
ogenic properties in specific cancer types. A further concern 
of the use of these cells as an anticancer delivery agent is the 
potential for malignant change, particularly in view of their 
capacity for proliferation.  
 In a patent published in 2006 by Furcht et al., methods 
for isolation of multipotent adult stem cells and its use for 
treating cancer are described. MSCs were genetically altered 
to express a tumoricidal protein, an anti-angiogenic protein, 
Table 1. Criteria for Defining Multi-Potent Human MSCs. 
Criteria Description 
Criterion I Cells being adherent to plastic under standard culture conditions 











and histocompatibility locus antigen (HLA)-DR 
Criterion III Under a specific stimulus, MSCs differentiate into osteocytes, adipocytes and chondrocytes both in vitro and in vivo.  
 
Table 2. MSCs as Anticancer Drug Delivery Systems. 
Anticancer Agent Effect References Experimental Model 
Interferon  (IFN) Therapeutic protein, apoptosis, decreased 
tumor mass and increased animal survival 
[17, 20, 23, 31, 32] Gliomas, mouse prostate cancer, lung metas-
tasis model, pancreatic tumors 
Interferon  (IFN) Therapeutic protein, immunostimulatory [31]  Mouse melanoma lung metastasis model 
Interleukin (IL)12 Immunostimulatory [33, 48, 49]  Lung and breast cancer 
Cytokine IL2 Immunomodulatory [34, 50] Rat glioma model 
Chemokine CX3CL1 Activates T cells and NK cells [22] Metastatic cancer 
Replicative oncolytic viruses Reduce tumor growth and spread in vivo [25, 36, 37] Lung and breast tumor models, metastatic cancer 
Cytoreagents for gene therapy and 
targeted chemotherapy 
Enzyme prodrug conversion [38, 39, 40, 41, 42, 43] Mice melanoma, human glioblastoma cells, 
pancreatic carcinoma, colon tumors 
Tumor necrosis factor-related 
apoptosis inducing ligand (TRAIL) 
Apoptosis [19, 45, 46, 47] Metastatic cancer, brain tumors, lung cancer 
model, intracranial glioma 
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or a protein expressed on the surface of a tumor cell in con-
junction with a protein associated with stimulation of an 
immune response to an antigen. In this invention, MSCs 
were promoted as a novel vehicle for cancer therapies that 
can be induced to differentiate to form endothelial cells or 
precursors which will home to endothelial tissues when de-
livered either locally or systemically. The cells participate in 
angiogenesis by integrating into the blood vessels in the 
newly-formed tumors. Upon stimulation, genetically engi-
neered cells undergo apoptosis and the newly-formed blood 
vessels can be disrupted and thus blood flow to the tumor 
can be eliminated [51]. An example of an externally-
delivered element would be the transfection/transduction of a 
gene that promotes apoptosis under control of a tetracycline 
response promoter [52]. In this system, the target gene can 
be activated by administration of doxycyline [52-54]. In 
2010, the same group published another invention that de-
scribed genetically modified MSCs that secrete products into 
the extracellular environment which are toxic to tumor cells 
or disrupt angiogenesis, such as pigment epithelium-derived 
factor (PEDF) [55]. Another approach is to utilize MSCs as a 
vector for delivering cancer vaccines. MSCs can be isolated 
from the patient, cultured ex vivo, genetically modified to 
express the appropriate antigens, and reintroduced into the 
subject to produce an immune response specific to the recep-
tors expressed on the tumor cells. 
 The use of MSCs and a demonstration of their various 
applications are given by Pittenger and Aggarwal in a patent 
published in 2011 [56]. The explained methods are for treat-
ing autoimmune disease, promoting wound healing, and in-
ducing angiogenesis in tissues and organs (Table 3). The 
authors have examined the interactions of MSCs with iso-
lated immune cells, including dendritic cells (DC1 and 
DC2), effector T-cells (Th1 and Th2), and NK cells. They 
discovered that MSCs may regulate the production of vari-
ous factors that could regulate several steps in the immune 
response. These findings may be employed in the treatment 
of disease conditions and disorders, including autoimmune 
diseases, allergies, arthritis, inflamed wounds, alopecia 
areata, and periodontal diseases. In addition, it is believed 
that MSCs stimulate peripheral blood mononuclear cells 
(PBMCs) to produce vascular endothelial growth factor, 
which stimulate the formation of new blood vessels. Fur-
thermore, it is believed that MSCs stimulate DCs to produce 
IFN, which promotes tumor suppression.  
 In another example, methods for stem cell therapy using 
direct inhibitors of lysophosphatidic acid (LPA) were pro-
vided [57]. Application of MSCs in two therapeutic areas 
(oncology and immune and inflammatory diseases) were also 
of interest in the recently published patent [58]. The authors 
aim to avoid a central problem in adult stem therapy, namely 
the inability to predict the behavior of transplanted cells in a 
patient’s body. One of the concerns is the purity of cells and 
the potential to transplant cell populations that already have 
been differentiated which may not act in the intended man-
ner. Here, methods for stimulating and isolating MSCs have 
been described. Stimulated MSCs (MSC1) compared to non-
stimulated MSCs (MSC2) demonstrated elevated secretion 
of IL4, IL6, IL8 and IL10, CXCL5, reduced secretion of 
transforming growth factor (TGF)1 and TGF3 and in-
creased indoleamine 2,3-dioxygenase activity. In one em-
bodiment, a method for treating ovarian cancer is provided 
by delivering isolated MSC incubated with at least one se-
lected Toll-like receptor ligand (TLR) for up to 2 h, where in 
vitro studies show divergent effect of MSC1 and MSC2 on 
co-cultures of different human cancer cell lines with MSC1 
and MSC2 [58].  
 TGF is also of interest in another invention that de-
scribes effective treatment of autoimmune diseases by 
TGF-incorporated MSCs [59]. According to a present dis-
closure, the authors provide a composition for treatment of 
autoimmune diseases including TGF-encoding MSCs in-
troduced with TGF-encoding nucleotide sequence and a 
pharmaceutically suitable carrier. The composition may be 
administered to the organism by any known method, for ex-
ample, orally or non-orally.  
 A new approach for targeting brain tumor cells has been 
developed using stem cells to deliver therapeutic agents to 
tumor areas. For targeted delivery, neural stem cells (NSCs) 
have been well studied and applied first. For example, a 
group of authors have demonstrated that neural stem cells 
(NSCs) possess significant migratory behavior with exten-
sive tropism to gliomas when administered intracranial [60-
63]. NSCs distribute throughout the primary tumor and mi-
grate together with widely outgrowing tumor microsatellites. 
Moreover, when NSCs are implanted intracranial at sites 
distant from the tumor, they migrate through the normal pa-
renchyma and localize in the tumor. This behavior of NSCs 
has been exploited as a tumor-targeting strategy for glioma 
gene therapy [42, 60-63].  
 The new invention, presented by Zhang et al. published 
in 2010 [64], provided technology for treatments of central 
nervous system (CNS) tumors with stem cells (Table 3). 
Briefly, the disclosure provides a modified stem cell con-
trolled-release vehicle with anti-neoplastic agent. A con-
trolled-release vehicle is selected from a group consisting of 
nanoparticles, biocompatible polymers, polymeric matrices, 
liposomes and lipospheres. The modified stem cells exhibit 
tropism to glioma cells, leading to a locally-concentrated 
dose of the anti-neoplastic agent which may kill or damage 
the target cells or tissues, resulting in destruction of the tu-
mor seen by reduction of the tumor size or volume. The 
modified stem cells may be administered after surgery, or to 
patients that for one or more reasons has not and/or cannot 
undergo surgery or conventional radiotherapy or chemother-
apy. In addition, for more effective therapy the modified 
stem cells may be loaded with more than one chemothera-
peutic agent for targeting neoplastic cells. 
 The use of magnetic nanoparticles for labeling MSCs in 
cancer treatment is given in a recently published invention 
by Janes et al. [65]. The authors developed a new technique 
that utilized MRI to track MSCs labeled with biocompatible 
iron oxide nanoparticles. They suggested that labeled-MSCs 
can be used for the delivery of anti-tumor factors directly to 
the site of tumors. Furthermore, the iron oxide nanoparticles 
incorporated into the MSCs can also be used to damage the 
tumor by thermotherapy. 
 An interesting approach given in the invention of Deng  
et al., is a combined use of MSCs and protein vaccine for 
treating cancer (Table 3) [66, 67]. The authors present a 
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method based on administration of a mammal-effective 
amount of stem cells encoding an oncogenic protein and a 
vaccine composition of immunogenic protein capable of 
eliciting an antibody specific effect against the oncogenic 
protein. Cancer vaccine therapy appears to be an attractive 
approach for cancer treatment because it has potential to 
target systemic tumors at multiple sites and specificity to 
distinguish healthy cells from neoplastic one. 
 Cancer can be initiated from epigenetic and genetic al-
terations of the genome presented as activation of oncogenes 
and inactivation of tumor-suppressor genes. The epigenetic 
alterations manifest as cell proliferation, inhibition of apop-
tosis and induction of angiogenesis. Whether a cell will ob-
tain a malignant phenotype or not depends on differentiation 
state and epigenetic conformation. A recently published in-
vention explains pharmaceutical compositions and methods 
for treatment of proliferative diseases such as cancer. The 
present invention is based on the fact that intra- and extracel-
lular components of cells, particular stem cells, can serve as 
a rich source of biomolecules. These biomolecules can be 
growth factors, cytokines, structural elements and transcrip-
tion factors, which can be involved in epigenetic repro-
gramming, or act to alter or reverse the malignant nature of 
the cancer cell and tissues [68]. 
MSCs GENETICALLY MODIFIED TO EXPRESS A 
SUICIDE GENE FOR TREATING A CANCER 
 MSCs expressing a suicide gene show excellent and 
highly selective anticancer effects. The method is based on 
selective conversion of a prodrug to an anticancer agent at 
the site of the cancer. Suicide genes are capable of convert-
ing a non-toxic prodrug to corresponding anticancer drug. 
For example, cytosine deaminase (CD) can convert 5-
fluorocytosine (5-FC) to cytotoxic 5-fluorouracil (5-FU) 
which kills neighboring cells (bystander effect). The direct 
administration of 5-FU cause’s cytotoxicity and leads to ad-
verse side effects, but combination of a suicidal gene and 5-
FC makes it possible to generate 5-FU selectively around 
tumor cells [69, 70]. Another example of a suicide gene is 
encoding herpes simplex type 1 thymidine kinase (HSV-
TK), which converts non-toxic gancyclovir into a toxic 
phosphorylated metabolite [38]. Patents published in 2010 
and 2012 by Nelson [71], provide a method for treating pa-
tients with pancreatic cancer through introducing a therapeu-
tically effective number of genetically modified MSCs by 
IV. Engineered MSCs can selectively express cytotoxic pro-
tein when they come into proximity of the tumor's stromal 
tissue. Briefly, the patents provide a method for treating pan-
creatic tumor in human subjects by CD34
-
 modified cells 
with herpes simplex viral thymidine kinase encoding region 
operable linked to a RANTES promoter. The method first 
introduces about 1 x 10
5
 to 1 x10
9
 cells/kg body weight of 
genetically modified CD34
-
 stem cells into the patient’s 
blood followed by gancyclovir in a manner permitting the 
herpes simplex viral thymidine kinase to render the gancy-
clovir cytotoxic.  
 The patent published in 2005 by Snyder et al. [72] relates 
to treatments of CNS tumors with modified and unmodified 
stem cells (Table 4). Particularly, the method explains sys-
temic treatment of CNS and other tumors using NSCs which, 
Table 3. Patents Subjected to MSCs and their Use. 
Patent/Year Inventor(s) Reference Description of the Invention 
US7015037  
(2006) 
Furcht, L.T, Verfaillie, C.M., 
Reyes, M.  
[51] MASCs isolation methods and MASCs as a novel vehicle 
for cancer therapies. 
US7659118  
(2010) 
Furcht, L.T., Verfaillie, C.M., 
Reyes, M.  
[55] Genetically altered MASCs toxic to tumor cells. 
US20110142807  
(2011) 
Pittenger, M.E., Aggarwal, S.  [56] MSC for treating autoimmune disease, promoting wound 
healing, and promoting angiogenesis. 
US20100055167  
(2010) 
Zhang, A., Guan, Y., Chen, L.  [64] Modified stem cells may be loaded with one or more 
chemotherapeutic agents for targeting neoplastic cell. 
US 20110027311  
(2011) 
Deng, W-P., Chang, H-K., Wei, 
H-C., Wu, T-H.A.  
[66] Combination of protein vaccine and MSC (encoding at 
least one oncogenic protein) for treating cancer. 
WO2012051210 
(2012) 
Betancourt, A.M. [58] MSCs and related therapies 
US20120207725 
(2012) 
Cho, S.G., Park, M.J., Park, 
H.S, Cho, M.L. 
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Pankhurst, Q. 








Sabbadini, R.A. [57] Stem cell therapy using inhibitors of LPA 
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like MSCs, fulfilled the requirement for cells with high mi-
gratory potential to the tumor and metastases site [73]. After 
a certain time, the stem cells migrate to the tumor site and 
systematically administered 5-FC would be converted by 
stem cells to toxic 5-FU [72]. 
 Another study exploited safe and effective anticancer 
agents through expression of a suicide gene in MSCs which 
migrate into brain cancer in an animal model (Table 4) [74]. 
The authors patented a kit for cancer treatment which con-
sists of an expression vector with a suicide gene, MSCs and 
a prodrug of an anticancer agent. They suggest bone marrow, 
peripheral blood or cord blood as a source for MSC isolation. 
 For the first time, stem cells have been used for detection 
and treatment of ovarian cancer in an invention published in 
2009 by Cady and McAsey (Table 4) [75]. Their method 
includes administering labeled stem cells to patients having, 
or suspected of having, a cancer and detecting the distribu-
tion of the stem cells. In some configurations, the label can 
be nanoparticles like mono-crystalline iron oxide which can 
be detected by magnetic resonance imaging. Treatment 
methods include administration of stem cells hosting a thera-
peutic agent such as an enzyme which converts the prodrug 
(5-FC) into a cytotoxic metabolite. 
MSCs MEDIATED VIRUS DELIVERY AND DELIV-
ERY OF THERAPEUTIC PROTEINS 
 A significant advantage of MSCs as cellular vehicles is 
that they are relatively easy to genetically manipulate in vi-
tro. In a majority of trials, adenovirus was used as a delivery 
vector. Low transfection efficiency using wild type adenovi-
ruses results from the fact that MSCs have low levels of ade-
novirus receptor and a high-integrin phenotype. Modification 
of the adenovirus with incorporation of an arginine-glycine-
aspartate section improves MSC transduction efficiency [36, 
37]. Newly generated conditionally replicating adenoviruses 
provides increased delivery of viral load specifically to the 
tumor site [25, 35, 37]. It is critically important to avoid 
premature toxicity to MSCs prior to engraftment at the target 
site. By using an adenovirus with relatively slow kinetics, 
one can avoid early cell death [76]. 
 One of the difficulties in the treatment of conditions such 
as cancer is the need to deliver large quantities of the thera-
peutic agent for extended periods of time. One approach is to 
use MSCs as micro carriers for protein delivery [77]. The 
invention of Paek from 2011 is based on this theory, and 
describes an adipose-derived stromal cell (ASC)-based de-
livery system for therapeutic delivery of biologically active 
anti-cancer agents. Some of the suggested deliverables to the 
tumor mass are anti-cancer protein molecules, apoptosis-
inducing molecules, or an agent that inhibits the expression 
of an oncogene. The authors showed that ASC populations 
migrate and home into the cancer tissue making it possible to 
deliver a high dose of an anti-cancer agent locally and di-
rectly to the tumor site. In addition, ASCs have a short half-
life in the circulation, so systemic non-specific responses 
will be minimal. This method allows the use of higher con-
centrations of the anti-cancer agents for more effective can-
cer treatment [78]. Integration of MSCs in the tumor stroma 
allows delivery of required dose of biological agents with 
short half-life or prominent toxicity. MSCs also can produce 
biological products at tumor sites and improve agents’ phar-
macokinetics [17]. One of the pioneering studies in this field 
is the work of Studeny et al. [79] where MSCs or stromal 
cell precursors were genetically modified to produce a thera-
peutic agent. The production of the therapeutic agent was 
localized in a specific area because gene modified cells pref-
erentially localize in the target microenvironment. Exem-
plary microenvironments include a tumor or a wound in a 
tissue and/or organ. An anticancer agent includes, but is not 
limited to cytokines, a hormone, an enzyme, a signaling 
molecule, or an anti-angiogenic polypeptide. The therapeutic 
agent may be IFN, IFN or similar. For example, with ani-
mal tumor models it has been shown that application of 
MSCs expressing IFN resulted in decreased tumor mass 
and increased animal survival. This fact brings new potential 
to the use of MSCs for regional secretion of IFN, because 
increased systemic levels of IFN and secretion at distant 
sites are not effective [20, 80]. Regional secretion is also 
required for a therapeutic effect of IL-12, and there are re-
ports of significant therapeutic effect of MSCs engineered to 
secrete IL-12 [48]. Furthermore, MSCs secreting IL-12 [33, 
48, 49] or IL-2 [34, 50] were shown to initiate an immunore-
Table 4. Patents Subjected to MSCs Genetically Modified to Express a Suicide Gene. 
Patent/Year Inventor(s) Reference Description of the invention 
US20050019313 
(2005) 
Snyder, E.Y., Aboody, K.S., 
Brown, A.B., Breakefield, X.O.  
[72] Method of systemic treatment of CNS and other tumors.  
US20080241115  
(2008) 
Suh, H-Y., Chang, D-Y., Kim, 
S-S., Yoo, S-W., Lee, Y-D.  
[74] Provides a kit for treating a cancer comprising an expres-








Nelson, P. [71] Genetically engineered MSCs and method of their use to 
treat tumors.  
US20120087901 
(2012) 
Nelson, P. [71] Engineered MSCs and methods of using them to treat 
tumors. 
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action and stimulate inflammatory cell infiltration in the tu-
mor tissue. Delivery of MSC-IL-12 increased tumor levels of 
IL-12 and did not cause systemic toxicity [49]. 
 MSCs secreting TRAIL have been used in different mod-
els of cancers in vivo, resulting in significant anti-tumor ef-
fects [19, 46, 47, 65, 81, 82]. On the other side, MSCs (like 
most healthy tissues) are resistant to TRAIL-induced apopto-
sis due to their low levels and/or inactive receptors [46]. In 
addition, in the TRAIL transfected adult mesenchymal stem 
cells, fetal-MSCs and umbilical cord matrix stem cells, there 
is almost undetectable levels of apoptotic pathway compo-
nents such as caspase-8 and -9 [83]. Delivery of this agent 
has advantages over some of the other anticancer MSC de-
livery systems described above since there appears to be very 
limited effects on non-cancerous tissues. Current clinical 
trials for TRAIL therapy in the form of recombinant protein 
and monoclonal antibodies show promising early results [84, 
85]. However, targeted delivery of TRAIL with MSCs over-
comes some of the problems which occurred in recombinant 
TRAIL therapy. MSC-TRAIL is more physiological than the 
monoclonal antibodies with much better half-life and deliv-
ery across the blood-brain barrier [1]. In an animal model 
study of lung cancer, local delivery of TRAIL by MSCs led 
to a reduction in tumor growth and significantly decreases 
lung metastases [19]. Also, therapeutic combination of the 
inhibitor of lipoxygenase MK886 and TRAIL-secreting hu-
man MSCs provided targeted and prolonged delivery of 
TRAIL in mouse models of glioma and in vitro [86]. The 
ability of TRAIL to selectively target tumor cells makes it an 
attractive candidate for therapy of malignant brain tumors 
[87]. In the invention of Shah, the methods of implantation 
of therapeutically engineered MSC with anti-tumor agents 
into tumor sites after surgery was presented. The results 
showed that MSC-TRAIL cytotoxic therapy is highly effec-
tive in inducing apoptosis and that TRAIL is a potent inhibi-
tor of brain tumor growth. It was suggested that the present 
approach would significantly improve treatment outcomes 
[87]. 
NEW CONCERNS ABOUT USE OF MSCs FOR TU-
MOR TREATMENT 
 Great progress has been made in the research of MSCs, 
which generated a significant amount of interest as a result 
of their ability to home to the tumor site after systemic deliv-
ery. The proposed use of MSCs in cancer therapies is con-
troversial, however, due to MSC promotion of tumor vascu-
larization, promotion of cancer progression and the invasive 
tendency of tumors have been previously reported [29, 88, 
89]. In some peritoneal cancers, like ovarian, bone delivered 
MSCs have been described as located around the tumor cells 
and in the ascitic fluid and no longer defined as multipotent 
as they are unable to differentiate in different cell lineages. 
They are defined as being carcinoma-associated (CA-MSCs) 
and present some characteristic markers of Carcinoma-
Associated Fibroblasts (CAFs) [90]. A few authors and their 
research groups recently published that MSCs also can be 
involved in the development of chemoresistance to different 
chemotherapies through the release of factors in the neigh-
borhood of tumors [91-95]. A number of targeted therapeu-
tics are currently under development targeting not only can-
cer cells but also cells from the microenvironment such as 
endothelial cells or mesenchymal stem cells. Although, these 
therapeutic approaches seem promising, they carry many 
side effects associated with the elimination of cells not in-
volved in cancer progression or in chemoresistance. This is 
only a brief overlook on this topic because there is still no 
evidence which supports this hypothesis, and hope still re-
mains as many authors have described cells from the micro-
environment which display several differences with their 
parent cells. Akimoto et al. [29] in their work isolated pri-
mary glioblastoma multiforme (GBM) cells and used MSC 
co-culture and co-transplantation assays to analyze charac-
teristics. They demonstrate that Umbilical cord blood-
derived MSCs (UCB-MSCs) inhibit GBM proliferative ac-
tivity, whereas Adipose tissue-derived MSCs (AT-MSCs) 
support GBM proliferation and presents their findings that 
the source of MSCs is very important for their clinical appli-
cation. Differences also lie between cells of the same origin 
but which have evolved differently depending on the organ 
and associated pathologies. Parental cells (such as macro-
phages, neutrophils or MSCs) can mostly be found with anti-
tumoral properties. In their study, Teng et al. [96] show that 
DNA hypermethylation within a specific tumor suppressor 
gene is sufficient to fully transform a somatic mesenchymal 
stem cell and proposed that under the influence of different 
environmental niches, these transformed stem cells could 
give rise to tissue-specific cancers. In agreement with previ-
ous reports suggesting contradictory effects of MSCs on tu-
mor cell proliferation [34, 38, 97], some types of MSC show 
tumor cell cytotoxicity, while others do not. The prolifera-
tion of some cancer cells was enhanced by adding MSCs to 
the culture [88, 89] while on the other hand, some groups 
have reported the anticancer activity of MSCs [17, 20, 23, 
42, 47, 97-99]. Conventional anticancer drug screening is 
typically performed in the absence of accessory cells of the 
tumor microenvironment, which can alter antitumor activity. 
Preclinical drug testing in the absence of relevant tumor mi-
croenvironment interactions may explain, at least in part, the 
gap between preclinical and clinical efficacy in cancers 
[100]. The inhibitory effect of MSCs on different types of 
tumor proliferation should be investigated before MSCs are 
used as a tool for drug delivery. However, very little is 
known about what actually causes the switch of a cell sur-
rounding a tumor from inhibiting tumor growth to tumor-
promoting. Therefore, given the evidence this hypothesis 
will be challenging. 
CURRENT & FUTURE DEVELOPMENTS 
 A central issue in cancer chemotherapy is the severe 
toxic side effects of anticancer agents on healthy tissues, 
which invariably imposes dose reduction, treatment delay or 
even discontinuance of therapy. Toxicity for healthy organs 
can be significantly diminished by employing a drug deliv-
ery systems which targets only cancer cells. The ultimate 
goal of this area of research is the development of an anti-
cancer therapy for humans and use of specific targeting to 
produce significantly less host toxicity than traditional agents 
and much higher local concentrations of antitumor agents. 
 Traditional chemotherapeutic agents are administered 
systemically. This may have undesirable side effects if the 
anti-cancer drug acts non-specifically on non-cancer cells, 
and may also result in only a small amount of the anti-cancer 
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drug actually reaching the site of the tumor. Additionally, the 
natural process of angiogenesis which provides vasculariza-
tion and nutrients to the tumor may causes a concomitant 
increase in the size of the tumor. In some instances an anti-
tumor drug or chemotherapeutic agent have been directed to 
the site of the tumor and specifically targets cancer cells us-
ing cell-surface targeting moieties, also called tumor associ-
ated antigens. However, even these methods suffer from a 
lack of effectiveness as the tumor associated antigens are not 
necessarily ubiquitous. 
 Accordingly, there is a need for more targeted tumor 
therapies. 
 This review highlights the potential for MSC-mediated 
delivery of therapeutic agents directly to tumor tissue based 
on the MSCs ability to localize and integrate into the tumor 
stroma. There are studies reporting engineered MSCs spe-
cifically targeting different tumor types followed by local 
secretion of therapeutic proteins such as, IFN and IFN, 
IL12, IL2 or CX3CL1. MSCs have also been engineered to 
deliver conditional replicative oncolytic viruses. Further-
more, MSCs serve as therapeutic cytoreagents for gene ther-
apy and vehicles for targeted chemotherapy with an enzyme 
prodrug conversion. Strong antitumor effects have been re-
ported following administration of gene modified MSCs 
expressing TRAIL. Further understanding of the biology of 
MSCs, and the specific combination of factors controlling 
their tumour-specific migration and persistence will help 
these technologies translate to the clinical setting. To ensure 
the safety of anticancer therapy using MSCs and in agree-
ment with previous reports suggesting contradictory effects 
of MSCs on tumor cell proliferation, the characteristics of 
MSCs themselves are quite important and should be investi-
gated before using an MSC-based therapy. 
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